Objectives: The objective of our work was to evaluate its prevalence and its different aspects.

Methods: A retrospective study including 11 files of GPA patients followed over a period of 10 years in The Internal Medicine Department at Tahar Sfar Hospital Mahdia TUNISIA.

Results: Neurological manifestations were reported in 5 patients: a pyramidal syndrome was noted in 3 patients with a normal cerebral MRI, a disabled headache was described in one patient with a normal cerebral MRI. Peripheral neuropathy in 2 cases, and the Electroneuromyogram objectified a mononeuropathy affecting the ulnar nerve, peroneal nerve, and musculocutaneous nerve in one patient and a distal sensitivomotor poly neuropathy in one patient. Cranial nerves damage was noted in two cases, one VII (1 case) and one V (1 case).

Conclusion: Our study results, show the importance of timely diagnosis of these neurological manifestations, as their evolution will depend on the early GPA treatment.

REFERENCES:

[1] doi: 10.1016/j.autrev.2017.07.007

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1660

AB0769

EROSIVE SYNOVITIS, DACTYLITIS, HYPERCALCAEMIA, LYMPHADENOPATHY, ELEVATED SERUM ACE & HYPOTHYROIDISM – AN UNUSUAL PRESENTATION OF IGG4-RELATED DISEASE

E. Tranah¹, A. Khan², N. Bhadauria¹, D. Mukerjee¹. ¹North Middlesex University Hospital, Rheumatology, London, United Kingdom; ²North Middlesex University Hospital, Rheumatology, London, United Kingdom

Background: IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder which can affect almost any tissue in the body. We describe a challenging case of IgG4-RD which reflects the great heterogeneity of this disease.

Objectives: A 49-year-old Mauritanian gentleman was referred to Rheumatology with chronic progressive symmetrical synovitis affecting the upper and lower limbs. He had no features suggestive of a spondyloarthropathy or connective tissue disease. Blood tests revealed a raised C-reactive peptide (CRP) of 194 mg/L and erythrocyte sedimentation rate (ESR) of 46 mm/hr. His rheumatoid factor and anti-cyclic citrullinated peptide antibodies were negative. Anti-nuclear antibody was weakly positive at 1:80 with a speckled pattern, but extractable nuclear antigen antibodies, anti-double-strand DNA-antibodies and anti-neutrophil cytoplasm antibodies were negative. Complement proteins and creatine kinase were normal. Radiographs of the hands and feet demonstrated widespread erosive changes worst at the metacarpophalangeal, metatarsophalangeal and first tarsometatarsal joints, as well as swan-neck deformities of the fifth phalanges in both hands. Chest radiograph and serological virology screen were both unremarkable. He was subsequently diagnosed with a seronegative inflammatory arthritis and treated with intramuscular methylprednisolone. He was awaiting subcutaneous methotrexate.

Methods: He was hospitalised shortly after with worsening polyarthritis and hypercalcaemia (3.34 mmol/L). Examination demonstrated synovitis, new lymphadenopathy and dactylitis. Other investigations revealed a normocytic anaemia (Hb 80 g/dL, MCV 80 fL), neutrophilia (20 x 10⁹/L), eosinophilia (4 x 10⁹/L), thrombocythaemia (500 x 10⁹/L), hypoalbuminaemia (25 g/L), CRP 200 mg/L and ESR 60 mm/hr. All immunoglobulins were raised with IgG 30.5 g/L. IgG4 subset was 3.0 g/L. Parathyroid hormone was low (< 0.7 pmol/L) and vitamin D was 125 nmol/L. Thyroid function, myeloma screen and blood tumour markers were unremarkable. Blood film revealed no blasts. Serum angiotensin-converting enzyme (ACE) was elevated at 171.9 U/L. A CT-chest-abdomen-pelvis revealed an enlarged thyroid with retrosternal extension and widespread lymphadenopathy above the diaphragm.

Results: Biopsies of the thyroid gland and submandibular lymph node demonstrated lymphoplasmacytic fibroinflammatory changes and > 40% of IgG4 cells. Neither biopsy showed evidence of sarcoidosis, tuberculosis or malignancy. He was treated with a weaning regimen of high-dose oral corticosteroids resulting in normalisation of haematological, inflammatory and biochemical parameters. His musculoskeletal pain, swelling and early morning stiffness significantly improved too. Subcutaneous methotrexate was commenced and titrated upwards to 20 mg. Two months later, his arthritis relapsed upon reduction of corticosteroids. Again, there was a marked inflammatory response with raised CRP and ESR. He had also developed a new hypothyroidism (TSH > 100 mU/L, T4 0.5 µg/dL, positive TPO-antibody). Repeat hand and feet radiographs

revealed severe erosive progressive disease (Figure 1). He awaits commencement of rituximab.

Figure 1. Plain hand radiograph demonstrating extensive erosive arthritis.

Conclusion: This is a unique presentation for a rare disease. There are few case reports of IgG4-RD causing erosive synovitis with rheumatoid-like swan-neck deformities or hypercalcaemia. Furthermore, this is the first case report as far as we know, of the disease associated with dactylitis or a raised serum ACE. Prior to biopsy, our main working diagnoses were sarcoidosis or a lymphoproliferative malignancy. The peculiar presentation necessitated a second opinion via the national IgG4-RD MDT who confirmed the histological diagnosis of IgG4-RD. We hope that this interesting case highlights the importance of histology in diagnosis of complex cases. In addition, the case presentation adds to the multitude of clinical manifestations of IgG4-RD.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1921

AB0770

A RARE CASE OF SYNOVIAL METASTASIS REVEALED BY KNEE PAIN

M. Yasmine¹, S. Miladi¹, A. Fazaa¹, S. Mariem¹, K. Ouenniche¹, L. Souebni¹, S. Kassab¹, S. Chekili¹, K. Ben Abdelghani¹, A. Laatar¹. ¹Mongi Slim Hospital, Rheumatology, Tunis, Tunisia

Background: Intra-articular masses are not frequently encountered in clinical practice. However, the differential diagnosis can be broad. Synovial metastasis is a rare presentation that carries a poor prognosis with a poor survival rate.

Objectives: Here by a case of synovial metastasis of the knee joint in a patient diagnosed with an adenocarcinoma of the lung.

Methods: A 60-year-old man with no remarkable past medical history presented to our department of rheumatology with right knee pain. He described a dull ache and swelling in his right knee with a dragging sensation, waking him up at night on a regular basis. The symptoms lasted for 6 months and were partially improved by analgesics and anti-inflammatory drugs. On examination, temperature was normal. The knee was edematous, erythematous, and warm with a range of motion of <90°. Laboratory investigations showed high acute phase reactants, the erythrocyte sedimentation rate was 75 mm. A plain radiograph of the left knee demonstrated a lytic lesion of the upper tibia. A magnetic resonance imaging of the right knee showed diffuse enlargement of the joint space due to a tissue infiltration within the synovium. These structures demonstrated heterogeneously increased T2 signal and intermediate T1 intensity characteristics. Most of the joint space was replaced by hyper enhancing synovium. At that time, differential considerations included severe inflammatory arthritis and synovial chondromatosis rather than unusual metastasis.

Results: Biopsy concluded to synovial metastasis from primary adenocarcinoma. Further investigations were necessary. Chest tomography showed a tumor process of left lower lobe associated with mediastinal lymphadenopathy. The patient was treated with palliative external radiotherapy to the right knee. The evolution was marked by the appearance of multiple tracheobronchial fistulas. The patient died 3 months later due to the progression of the disease.

Conclusion: We report a rare case of synovial metastasis concomitant to a lung adenocarcinoma. It is important to make a rapid diagnosis as early recognition of malignant infiltration into joints ensure appropriate multidisciplinary management decisions.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.2143

AB0771

HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT OF VISUAL ACUITY IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES

N. Vegas-Revenge¹, J. L. Martín-Varillas², V. Calvo-Río³, I. González-Mazón³, L. Sanchez-Bilbao³, E. Beltrán⁴, A. Fonollosa⁵, O. Maiz-Alonso⁶, A. Blanco⁷, M. Cordero-Coma⁸, N. Ortego⁹, I. Torre-Salaberri¹⁰, F. Francisco¹¹, S. Muñoz Fernandez¹², M. D. M. Esteban-Ortega¹³, M. Díaz-Llopis¹⁴, J. Cañal¹⁵, J. A. Ventosa¹⁵, R. Demetrio-Pablo¹⁵, L. Domínguez¹⁶, M. Agudo-Bilbao³, S. Castañeda¹⁷, I. Ferraz-Amaro¹⁸, M. A. González-Gay³, R. Blanco³.
¹Hospital Galdakao-Usansolo, Rheumatology, Galdakao, Spain; ²Hospital de Sierrallana, Rheumatology, Torrelavega, Spain; ³Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain; ⁴Hospital Universitario Doctor Peset, Rheumatology, Valencia, Spain; ⁵Hospital Universitario de Cruces, Ophthalmology, Barakaldo, Spain; ⁶Hospital Universitario Donostia, Rheumatology, San Sebastian, Spain; ⁷Hospital Universitario Donostia, Ophthalmology, San Sebastian, Spain; ⁸Hospital de León, Ophthalmology, León, Spain; ⁹Hospital Universitario San Cecilio, Ophthalmology, Granada, Spain; ¹⁰Hospital Universitario de Basurto, Rheumatology, Bilbao, Spain; ¹¹Hospital Universitario de Gran Canaria Doctor Negrín, Rheumatology, Gran Canaria, Spain; ¹²Hospital Universitario Infanta Sofía, Rheumatology, Madrid, Spain; ¹³Hospital Universitario Infanta Sofía, Ophthalmology, Madrid, Spain; ¹⁴Hospital Universitario La Fe, Ophthalmology, Valencia, Spain; ¹⁵Hospital Universitario Marqués de Valdecilla, Ophthalmology, Santander, Spain; ¹⁶Hospital Universitario San Agustín, Rheumatology, Avilés, Spain; ¹⁷Hospital Universitario de la Princesa, Rheumatology, Madrid, Spain; ¹⁸Hospital Universitario de Canarias, Rheumatology, Canarias, Spain

Background: Rapid and effective remission-inducing therapy is mandatory in uveitis to avoid irreversible structural and functional damage. In some severe cases biological agents might be required (1-6).

High-dose intravenous methylprednisolone (IVMP) may achieve prompt control of inflammation in most immune mediated inflammatory diseases (IMID), including non-infectious uveitis (NIU).

Objectives: To evaluate the efficacy and safety of IVMP pulse therapy in NIU of different IMID.

Methods: Multicentre study of 71 patients with severe uveitis who received IVMP. The underlying diseases were: Vogt Koyanagi Harada disease (VKHD) (n=24), Behçet disease (BD) (19), Sarcoidosis (5) and idiopathic NIU (23). The main outcome variable was Best-Corrected Visual Acuity (BCVA) estimated using the Snellen chart. BCVA that was assessed at 0 (basal), 2-5, 7, 15 and 30 days after IVMP.

The results are expressed as mean $\pm$ SD in normally distributed variables, or as median [IQR] when are not. Comparison of continuous variables was performed using the Wilcoxon test.

Results: We studied 46♀/25♂ patients. The main features are shown in Table 1. IVMP dose ranged from 250 to 1000mg/day administered for 3-5 consecutive days, the dose was established according to the presence or not of other systemic manifestations apart from uveitis. All of them had active intraocular inflammation at the moment of the study. BCVA values improved considerably after 1 month (Figure 1). No major side effects were observed.

Figure 1. Improvement of best corrected visual acuity (BCVA).

Conclusion: High-dose IVMP pulse therapy is useful and safe for a prompt control of BCVA regardless of the underlying IMID.

REFERENCES:

- [1] Vegas-Revenge N, et al. Am J Ophthalmol. 2019; 200:85-94. doi: 10.1016/j.ajo.2018.12.019
- [2] Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576
- [3] Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359
- [4] Atienza-Mateo B, et al. Rheumatology (Oxford) 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480.
- [5] Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026.
- [6] Martín-Varillas JL, et al. Ophthalmology. 2018;125(9):1444-1451. doi: 10.1016/j.optha.2018.02.020

Table 1. Main features of 71 patients with NIU. Data are of affected eyes.

	VKHD (n=24)	Idiopathic (n=23)	Behçet's disease (n=19)	Sarcoidosis (n=5)	Overall (n=71)
Men/Women, n	5/19	9/14	9/10	2/3	71
Mean age (years) $\pm$ SD	42 $\pm$ 11	47 $\pm$ 15	33 $\pm$ 10	42 $\pm$ 22	-
Unilateral/Bilateral	2 (8.3)/22(91.7)	10 (43.5)/13(56.5)	4 (21)/15 (79)	3(60)/2(40)	19/52
NIU, n (%)					
NIU patterns, n (%)					
Posterior uveitis	6 (25)	9 (39.1)	3 (15.8)	1 (20)	19
Panuveitis	18 (75)	14 (60.9)	16 (84.2)	4 (80)	52
Laboratory data, n (%)					
ANA	2 (8.34)	2 (8.7)	0 (0)	1 (20)	5
HLA B27	0 (0)	4 (17.4)	0 (0)	0 (0)	4
HLA B29	0 (0)	1 (4.3)	0 (0)	0 (0)	1
HLA B51	0 (0)	5 (21.7)	8 (42)	3 (60)	16
Angiotensin Converting Enzyme (ACE)	1 (4.17)	2 (8.7)	0 (0)	1 (20)	4

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.2159

AB0772

JAK INHIBITORS IN REFRACTORY ADULT AND CHILDHOOD ONSET STILL'S DISEASE

L. Gillard¹, S. Mitrovic^{1,2}, H. Reumaux³, M. Michaud⁴, F. Cohen^{1,2}, J. Pouchot⁵, B. Fautrel^{1,2,6}. ¹Pitié-Salpêtrière, AP-HP, Rheumatology Department, Paris, France; ²Sorbonne Université, Rheumatology Department, Paris, France; ³Jeanne de Flandre Hospital, Rheumatology, Lille, France; ⁴Hospital Joseph Ducuing, Médecine Interne, Toulouse, France; ⁵European Hospital Georges Pompidou, Médecine Interne, Paris, France; ⁶Pierre Louis Institute of Epidemiology and Public Health, INSERM UMR 1136, Paris, France

Background: Excessive and inappropriate production of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 or IL-18, is a pathogenic cornerstone in adult and childhood onset Still's disease. Beyond therapies targeting IL-1 or IL-6, Janus kinases (JAK) inhibitors have been proposed for adult-onset Still's disease (AOSD) patients refractory to or intolerant of treatment with biologicals. Recently, it has been suggested that JAK inhibitors might be efficient in refractory AOSD patients¹.

Objectives: To assess the efficacy and safety of JAK inhibitors in the treatment of refractory systemic juvenile idiopathic arthritis (sJIA) or AOSD.

Methods: This retrospective study was based on a national survey of the departments of rheumatology, paediatric rheumatology and internal medicine in all French hospitals from an online call of the "Club Rhumatismes et Inflammation" (www.cri-net.com). The data were collected using a standardized questionnaire, and analyzed at different time points (treatment initiation, M1, M3, M6 and end of the follow-up). The response to JAK inhibitors was categorized as: complete remission (resolution of all clinical and biologic signs), partial remission (clinical improvement with persistence of a few symptoms) or failure (lack of clinical or biological improvement).

Results: 6 patients (5 adults and 1 child) were recruited (Table 1). Mean age at treatment start was 39.6 years for the AOSD patient and 6 years for the sJIA patient, and mean disease duration was 5.3 years. The clinical expression was predominantly systemic in 5 five patients and chronic articular in one. Response to corticosteroids, conventional synthetic or biological Disease Modifying Anti-Rheumatic Drugs had been considered inadequate in all patients. Baricitinib was used in 3 patients, ruxolitinib in 2, and tofacitinib in 1. Steroids were concurrently used in all patients, anakinra in one, methotrexate and anakinra in one. At a mean (SD) follow-up of 9.5 months, partial response was observed in 4 (66.7%) cases (patients with ruxolitinib, tofacitinib